About the Journal
Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.Read More About the Journal
Noted This Week
The FDA approved azacitidine (Vidaza; Celgene) for children with newly diagnosed juvenile myelomonocytic leukemia. The decision was based on the AZA-JMML-001 trial, in which 18 patients received azacitidine prior to hematopoietic stem cell (HSC) transplantation. Three patients experienced clinical complete remission (CR) and six experienced clinical partial remission, with a median time to response of 1.2 months; 94% underwent HSC transplantation, with a median time to transplantation of 4.6 months.